Literature DB >> 32069503

Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions.

Fredrik Åberg1,2, Martti Färkkilä3.   

Abstract

Alcohol and obesity are the main risk factors for alcoholic liver disease and nonalcoholic fatty liver disease (NAFLD), respectively, and they frequently coexist. There are considerable synergistic interaction effects between hazardous alcohol use and obesity-associated metabolic abnormalities in the development and progression of fatty liver disease. Intermittent binge-drinking has been shown to promote steatohepatitis from obesity-related steatosis, and binge-drinking is associated with progression to cirrhosis even when average alcohol intake is within the currently used criteria for a NAFLD diagnosis. Recent longitudinal studies in NAFLD have shown that light-to-moderate alcohol use is associated with fibrosis progression and incident clinical liver disease, suggesting that there is no liver-safe limit of alcohol intake in the presence of NAFLD; a J: -shaped association between alcohol and all-cause mortality remains controversial. The interaction effects between alcohol and obesity make the present strict dichotomization of liver disease into alcoholic and NAFLD inappropriate, and require attention in future research, public health policy, individual counseling, and risk stratification. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2020        PMID: 32069503     DOI: 10.1055/s-0040-1701443

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  12 in total

1.  Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.

Authors:  Hannes Hagström; Leon A Adams; Alina M Allen; Christopher D Byrne; Yoosoo Chang; Henning Grønbaek; Mona Ismail; Peter Jepsen; Fasiha Kanwal; Jennifer Kramer; Jeffrey V Lazarus; Michelle T Long; Rohit Loomba; Philip N Newsome; Ian A Rowe; Seungho Ryu; Jörn M Schattenberg; Marina Serper; Nick Sheron; Tracey G Simon; Elliot B Tapper; Sarah Wild; Vincent Wai-Sun Wong; Yusuf Yilmaz; Shira Zelber-Sagi; Fredrik Åberg
Journal:  Hepatology       Date:  2021-06-22       Impact factor: 17.298

2.  Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis.

Authors:  Helen Jarvis; Hannah O'Keefe; Dawn Craig; Daniel Stow; Barbara Hanratty; Quentin M Anstee
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

Review 3.  Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.

Authors:  Luca Maccioni; Isabelle A Leclercq; Bernd Schnabl; Peter Stärkel
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 6.208

Review 4.  Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease.

Authors:  Julie Massart; Karima Begriche; Anne Corlu; Bernard Fromenty
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

Review 5.  Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.

Authors:  Agostino Di Ciaula; Leonilde Bonfrate; Marcin Krawczyk; Gema Frühbeck; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

6.  Therapeutic Effects of Bee Bread on Obesity-Induced Testicular-Derived Oxidative Stress, Inflammation, and Apoptosis in High-Fat Diet Obese Rat Model.

Authors:  Joseph Bagi Suleiman; Mahaneem Mohamed; Ainul Bahiyah Abu Bakar; Zaida Zakaria; Zaidatul Akmal Othman; Victor Udo Nna
Journal:  Antioxidants (Basel)       Date:  2022-01-28

7.  Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study.

Authors:  Yoshihiro Kamada; Koichi Morishita; Masahiro Koseki; Mayu Nishida; Tatsuya Asuka; Yukiko Naito; Makoto Yamada; Shinji Takamatsu; Yasushi Sakata; Tetsuo Takehara; Eiji Miyoshi
Journal:  Nutrients       Date:  2020-06-12       Impact factor: 5.717

8.  Differential role of MLKL in alcohol-associated and non-alcohol-associated fatty liver diseases in mice and humans.

Authors:  Tatsunori Miyata; Xiaoqin Wu; Xiude Fan; Emily Huang; Carlos Sanz-Garcia; Christina K Cajigas-Du Ross; Sanjoy Roychowdhury; Annette Bellar; Megan R McMullen; Jaividhya Dasarathy; Daniela S Allende; Joan Caballeria; Pau Sancho-Bru; Craig J McClain; Mack Mitchell; Arthur J McCullough; Svetlana Radaeva; Bruce Barton; Gyongyi Szabo; Srinivasan Dasarathy; Laura E Nagy
Journal:  JCI Insight       Date:  2021-02-22

9.  An Experimental DUAL Model of Advanced Liver Damage.

Authors:  Raquel Benedé-Ubieto; Olga Estévez-Vázquez; Feifei Guo; Chaobo Chen; Youvika Singh; Helder I Nakaya; Manuel Gómez Del Moral; Arantza Lamas-Paz; Laura Morán; Nuria López-Alcántara; Johanna Reissing; Tony Bruns; Matías A Avila; Eva Santamaría; Marina S Mazariegos; Marius Maximilian Woitok; Ute Haas; Kang Zheng; Ignacio Juárez; José Manuel Martín-Villa; Iris Asensio; Javier Vaquero; Maria Isabel Peligros; Josepmaria Argemi; Ramón Bataller; Javier Ampuero; Manuel Romero Gómez; Christian Trautwein; Christian Liedtke; Rafael Bañares; Francisco Javier Cubero; Yulia A Nevzorova
Journal:  Hepatol Commun       Date:  2021-03-11

Review 10.  The Expression and Function of Circadian Rhythm Genes in Hepatocellular Carcinoma.

Authors:  Yanan Jiang; Xiuyun Shen; Moyondafoluwa Blessing Fasae; Fengnan Zhi; Lu Chai; Yue Ou; Hai Feng; Siwei Liu; Ying Liu; Shucai Yang
Journal:  Oxid Med Cell Longev       Date:  2021-10-16       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.